



04-11-03 1645
Docket No: AM100369
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: BATES, B. G. et al.
Serial No.: 10/027,923 Group Art No.: 1645
Filed: December 21, 2001 Examiner: #7
For: NOVEL GLUTAMATE RECEPTOR MODULATORY PROTEINS
AND NUCLEIC ACID MOLECULES AND USES THEREFOR
Confirmation No.: 9899
Customer Number: 25291

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RECEIVED

APR 14 2003

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV100598272US addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

April 9, 2003
Date

Carole K. Kamrad
Carole K. Kamrad

2. Identification of Time of Filing

This Information Disclosure Statement

- a. ☐ is filed within three months of the filing date of the application.
- b. ☒ is filed before the mailing date of a first Office Action on the merits.
- c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. ☐ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☐ Certification under 37 CFR 1.97(e) and 1.704(d)
The undersigned attorney certifies

- a. ☐ that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. ☐ The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

☒ Newly Cited Information
A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed.

☐ Previously Cited Information
No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.

Prior application is Serial Number _____, filed on _____ of _____ for _____.

- ☐ Concise Explanation
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
- b. ☐ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

- ☐ Fees
- ☐ Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00

Method of Payment of Fees:

Charge Deposit Account No. 01-1425 in the amount of \$0.00

A duplicate of this statement is enclosed.


Instructions as to Overpayment/Underpayment:

Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.



Bill T. Brazil
Agent for Applicants
Reg. No. 50,733

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (732) 274-4843



Substitute for form 144B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/027,923
(Use as many sheets as necessary)		Filing Date	12/21/01
		First Named Inventor	Brian G. Bates
		Group Art Unit	1645
		Examiner Name	
Sheet 1 of 1		Attorney Docket Number	AM100369

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	1		WO 94 29449	A1	Salk Inst. Biotech	12-22-1994		<input type="checkbox"/>
	2		WO 99 38975	A2	Univ. Technology Corp.	08-05-1999		
	3		WO 01 30829	A1	NPS Pharma Inc.	05-03-2001		
	4		WO 01 77291	A2	Genetics Inst.	10-18-2001		

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	5.	ABE, T. et al. "Molecular Characterization of a Novel Metabotropic Glutamate Receptor mGluR5 Coupled to Inositol Phosphate/ Ca^{2+} Signal Transduction", <i>Journal of Biological Chemistry</i> , 267:13361-13368 (1992)	<input type="checkbox"/>
	6.	HEPLER, J. R., "Emerging roles for RGS proteins in cell signalling" <i>TiPs</i> , 20: 376-382 (1999)	
	7.	KRAPPA, R., et al. "Evectins: Vesicular proteins that carry a pleckstrin homology domain and localize to post-Golgi membranes" <i>Proc. Natl. Acad. Sci.</i> , 96: 4633-4638 (1999)	
	8.	MALHERBE, P. et al, "Identification and Characterization of a Novel Splice Variant of the Metabotropic Glutamate Recdeptor 5 Gene in Human Hippocampus and Cerebellum", <i>Molecular Brain Research</i> , 109: 168-178 (2002)	<input type="checkbox"/>
	9.	MELDRUM, B.S., "Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology", <i>Journal of Nutrition</i> , 130: 1007S-1015S (2000)	<input type="checkbox"/>
	10.	MINAMI, K. et al. "Effects of Ethanol and Anesthetics on Type 1 and 5 Metabotropic Glutamate Receptors Expressed in <i>Xenopus laevis</i> Oocytes", <i>Molecular Pharmacology</i> , 53:148-156 (1998)	<input type="checkbox"/>
	11.	PIN, J-P et al., "Neurotransmitter Receptors I. The Metabotropic Glutamate Receptors: Structure and Functions", <i>Neuropharmacology</i> , 34:1-26 (1995)	<input type="checkbox"/>
	12.	RAHMAN, Z., et al. "Cloning and characterization of RGS9-2: A striatal-enriched alternatively spliced product of the RGS9 gene" <i>The Journal of Neuroscience</i> , 19(6): 2016-2026 (1999);	
	13.	ROSS, E. M., and T. M. Wilkie, "GTPASE-activating proteins for heterotrimeric G proteins: Regulators of G protein signaling (RGS) and RGS-like proteins" <i>Annu. Rev. Biochem.</i> , 69: 795-827 (2000)	
	14.	XU, S., "PHR1 encodes an abundant, pleckstrin homology domain-containing integral membrane protein in the photoreceptor outer segments" <i>The Journal of Biological Chemistry</i> , 274(50): 35676-35685 (1999)	

RECEIVED
APR 14 2003
TECH CENTER 1600/2900

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.